Please login to the form below

Not currently logged in
Email:
Password:

MOV-e-AHEAD

This page shows the latest MOV-e-AHEAD news and features for those working in and with pharma, biotech and healthcare.

Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention

Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention

Merck, known as MSD outside the US and Canada, and Ridgeback Biotherapeutics have announced that its MOV-e-AHEAD study has started to enrol its first participants to test antiviral molnupiravir ... It was recently announced that Health Canada will

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....